iec1 Antibody

What is ECI1 and why is it significant in research?

ECI1, also known as enoyl-CoA delta isomerase 1, is a critical enzyme involved in fatty acid oxidation pathways and plays an essential role in maintaining cellular lipid homeostasis. The significance of ECI1 in research stems from its implications in metabolic disorders including obesity, diabetes, and cardiovascular disease . Studying ECI1 using specific antibodies allows researchers to investigate lipid metabolism mechanisms and potential therapeutic interventions for metabolic disorders. The protein is primarily localized in the mitochondrial matrix, making it a valuable marker for mitochondrial function studies .

What applications are ECI1 antibodies validated for?

ECI1 antibodies, such as the Rabbit Polyclonal Antibody (CAB1211), have been validated for multiple research applications including:

• Western blot (WB) at dilutions of 1:500 - 1:2000

• Immunohistochemistry on paraffin-embedded tissues (IHC-P) at dilutions of 1:50 - 1:200

• Immunofluorescence/Immunocytochemistry (IF/ICC) at dilutions of 1:50 - 1:200

• Enzyme-Linked Immunosorbent Assay (ELISA)

This versatility allows researchers to select the most appropriate method based on their specific research questions and available sample types.

What cell lines can be used as positive controls for ECI1 antibody validation?

According to validation data, recommended positive control cell lines for ECI1 antibody testing include:

• HeLa cells (human cervical cancer cell line)

• RAW 264.7 cells (mouse macrophage cell line)

Using these established positive controls helps researchers verify antibody performance before proceeding to experimental samples.

What is the immunogen sequence used for generating ECI1 antibodies?

The immunogen used for generating ECI1 polyclonal antibodies corresponds to a recombinant fusion protein containing amino acids 63-302 of human ECI1 (NP_001910.2) . The specific amino acid sequence is:

KNPPVNSLSLEFLTELVISLEKLENDKSFRGVILTSDRPGVFSAGLDLTEMCGRSPAHYAGYWKAVQELWLRLYQSNLVLVSAINGACPAGGCLVALTCDYRILADNPRYCIGLNETQLGIIAPFWLKDTLENTIGRAAERALQLGLLFPPEALQVGIVDQVVPEEQVQSTALSAIAQWMAIPDHARQLTKAMMRKATARLVTQRDADVQNFVSFISKDSIQKSLQMYLERLKEEKG

Understanding the immunogen is crucial for researchers to assess potential cross-reactivity and epitope specificity.

How should I optimize antibody dilutions for Western blot when using ECI1 antibodies?

When optimizing ECI1 antibody dilutions for Western blot, begin with a dilution range of 1:500 - 1:2000 as recommended . To determine the optimal dilution:

• Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000)

• Run identical Western blots with positive control samples (HeLa or RAW 264.7 cell lysates)

• Compare signal-to-noise ratios across dilutions

• Select the dilution that provides the strongest specific signal with minimal background

For challenging samples, consider lengthening the primary antibody incubation time to overnight at 4°C rather than increasing concentration, as this often improves sensitivity while maintaining specificity.

What fixation methods are optimal for immunohistochemistry with ECI1 antibodies?

When performing IHC-P with ECI1 antibodies, fixation methods significantly impact epitope preservation and antibody binding. Based on general IHC principles from the search results:

• Standard fixation with 10% neutral buffered formalin for 24-48 hours is generally suitable

• Overfixation should be avoided as it can mask epitopes through excessive protein cross-linking

• For mitochondrial proteins like ECI1, ensure tissue dehydration is gradual to preserve subcellular structures

• Consider antigen retrieval methods, with citrate buffer (pH 6.0) heat-induced epitope retrieval often being effective for mitochondrial proteins

The objective is to preserve tissue morphology while maintaining target antigen accessibility for the antibody.

How can I validate the specificity of ECI1 antibody staining in immunofluorescence experiments?

Validating ECI1 antibody specificity in immunofluorescence requires multiple controls:

• Positive controls: Use cell lines known to express ECI1 (HeLa, RAW 264.7)

• Negative controls:

  • Omit primary antibody to assess secondary antibody non-specific binding

  • Use cell lines with confirmed low/no ECI1 expression

• Peptide competition: Pre-incubate the antibody with excess immunizing peptide (amino acids 63-302 of human ECI1) to block specific binding sites

• Co-localization: Confirm mitochondrial localization using established mitochondrial markers

• Knockdown validation: Compare staining in wild-type cells versus ECI1-knockdown cells

Quantitative analysis of signal intensity and distribution patterns provides additional validation metrics.

What are the best approaches to quantitatively analyze ECI1 expression in tissue samples?

For quantitative analysis of ECI1 expression in tissues, consider these methodological approaches:

• Standardized quantitative immunofluorescence (QIF):

  • Similar to methods described for ER quantification, establish a standardized index of controls spanning the expression range

  • Use automated image analysis software to measure signal intensity within defined cellular compartments (e.g., mitochondria)

  • Calculate signal-to-noise ratios to determine threshold for positivity

• Tissue microarray (TMA) standardization:

  • Include reference controls on each TMA slide to normalize across batches

  • Report AQUA scores (Automated Quantitative Analysis) or similar standardized metrics

• Sequential staining protocol:

  • Counterstain with mitochondrial markers to normalize ECI1 expression to mitochondrial content

  • Consider dual staining with markers of interest to correlate ECI1 expression with cellular processes

What strategies can address cross-reactivity concerns when studying ECI1 in mouse models?

When using ECI1 antibodies across species (particularly in mouse models), consider these strategies to address potential cross-reactivity issues:

• Sequence homology analysis: Compare the immunogen sequence (amino acids 63-302 of human ECI1) with the corresponding mouse sequence to identify regions of divergence

• Western blot validation: Run parallel blots with human and mouse tissue lysates to confirm band patterns align with predicted molecular weights

• Knockout controls: If available, include ECI1-knockout mouse tissues as negative controls

• Epitope mapping: If cross-reactivity is observed, determine which specific epitopes are responsible through peptide mapping experiments

• Antibody pre-absorption: Pre-absorb the antibody with recombinant mouse ECI1 protein to reduce species cross-reactivity when studying human samples

Despite the antibody being reported as reactive to both human and mouse samples , species-specific validation is crucial for accurate interpretation of results.

How should researchers interpret variations in ECI1 expression across different cell types?

When interpreting variations in ECI1 expression across cell types:

• Baseline expression levels: Establish normal expression ranges in tissues of interest using reference databases and control samples

• Metabolic context: Consider the metabolic profile of each cell type, as cells with high fatty acid oxidation requirements (e.g., cardiomyocytes, hepatocytes) typically express higher levels of ECI1

• Subcellular distribution: Assess not only total protein levels but also subcellular localization patterns, as redistribution may indicate functional changes

• Correlation analysis: Correlate ECI1 expression with functional endpoints relevant to lipid metabolism

• Isozyme expression: Consider the relative expression of ECI1 versus other fatty acid metabolism enzymes for comprehensive pathway analysis

Expression differences should be interpreted within the physiological context of each cell type's metabolic requirements.

What are the critical considerations when comparing results from different antibody clones targeting ECI1?

When comparing results from different antibody clones targeting ECI1, researchers should consider:

• Epitope differences: Different antibodies may target distinct epitopes on ECI1, affecting detection of post-translational modifications or protein isoforms

• Antibody format: Compare polyclonal versus monoclonal antibodies systematically:

• Standardization approach: Implement standardized quantification methods similar to those described for ER antibody comparison

• Discordance analysis: When antibodies give discrepant results, examine cases specifically to determine if:

  • One antibody has superior sensitivity

  • Differences relate to specific post-translational modifications

  • Technical factors affect staining patterns

• Outcome correlation: For discrepant cases, correlate results with functional endpoints to determine which antibody provides biologically relevant information

How can ECI1 antibodies be utilized in studying metabolic disease models?

ECI1 antibodies can be valuable tools in metabolic disease research through:

• Tissue expression profiling:

  • Compare ECI1 expression in tissues from healthy subjects versus patients with metabolic disorders

  • Correlate expression with disease progression markers

• Intervention studies:

  • Monitor changes in ECI1 expression during therapeutic interventions targeting lipid metabolism

  • Use immunostaining to assess subcellular redistribution following treatment

• Pathway analysis:

  • Combine with antibodies against other fatty acid oxidation enzymes for comprehensive pathway assessment

  • Implement multiplex immunofluorescence to simultaneously visualize multiple metabolic enzymes

• Functional correlation:

  • Correlate ECI1 expression with functional measurements of mitochondrial fatty acid oxidation

  • Assess relationship between ECI1 levels and lipid accumulation in tissues

Given ECI1's role in lipid metabolism and its implication in conditions like obesity and diabetes , antibody-based detection provides valuable insights into disease mechanisms.

What considerations are important when using ECI1 antibodies for co-immunoprecipitation studies?

When using ECI1 antibodies for co-immunoprecipitation (Co-IP) studies:

• Buffer optimization:

  • Use gentle lysis buffers that preserve protein-protein interactions while efficiently extracting mitochondrial proteins

  • Consider specialized mitochondrial isolation protocols before immunoprecipitation

• Antibody suitability assessment:

  • Test whether the antibody recognizes native (non-denatured) ECI1 protein

  • Determine optimal antibody-to-lysate ratios through titration experiments

• Controls:

  • Include isotype controls to identify non-specific binding

  • Perform reverse Co-IP to confirm interactions

  • Include negative controls (e.g., immunoprecipitation from ECI1-depleted cells)

• Verification strategies:

  • Confirm immunoprecipitated proteins by Western blot

  • Consider mass spectrometry analysis for unbiased identification of interaction partners

• Crosslinking considerations:

  • For transient interactions, consider using chemical crosslinkers before cell lysis

  • Optimize crosslinking conditions to prevent artifactual interactions

How do polyclonal ECI1 antibodies compare to monoclonal alternatives in specific research applications?

While the search results primarily discuss a polyclonal ECI1 antibody (CAB1211) , researchers should understand the comparative advantages:

When selecting between polyclonal and monoclonal antibodies, consider the specific requirements of your experimental system and the critical parameters for your research question.

What strategies can improve signal detection when working with low-abundance ECI1 expression?

For challenging samples with low ECI1 expression, implement these signal enhancement strategies:

• Signal amplification systems:

  • Tyramide signal amplification (TSA) can enhance fluorescent signal up to 100-fold

  • Polymer-based detection systems can significantly increase chromogenic signal in IHC

• Sample preparation optimization:

  • Optimize antigen retrieval for enhanced epitope accessibility

  • Consider using thinner tissue sections (3-4 μm) for better antibody penetration

• Imaging enhancements:

  • Implement quantitative imaging similar to methods described for ER detection

  • Use advanced microscopy techniques (e.g., confocal, deconvolution) to improve signal-to-noise ratio

  • Consider computational image enhancement while maintaining data integrity

• Protocol modifications:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize blocking to reduce background while preserving specific signal

  • Consider alternative fixation methods that better preserve ECI1 epitopes

• Enrichment approaches:

  • For certain applications, consider mitochondrial enrichment before analysis

  • Implement proximity ligation assays (PLA) for detecting protein interactions with enhanced sensitivity

How can ECI1 antibody studies be integrated with transcriptomic data for comprehensive pathway analysis?

Integrating ECI1 antibody-based protein detection with transcriptomic data provides powerful insights:

• Correlation analysis:

  • Compare protein expression levels (by Western blot or IHC quantification) with ECI1 mRNA levels

  • Identify potential post-transcriptional regulation mechanisms when protein and mRNA levels diverge

• Cell-type specific analysis:

  • Use single-cell transcriptomics to identify cell populations with high ECI1 expression

  • Target these specific populations with immunohistochemistry for validation

• Pathway integration:

  • Correlate ECI1 protein levels with expression of other genes in fatty acid metabolism pathways

  • Develop integrated models incorporating both transcriptomic and proteomic data

• Perturbation studies:

  • Assess how genetic or pharmacological interventions affect both ECI1 mRNA and protein levels

  • Identify regulatory mechanisms governing ECI1 expression

• Temporal analysis:

  • Track changes in both ECI1 transcript and protein levels during disease progression or treatment

This integrated approach provides more comprehensive insights than either method alone.

What are the best practices for using ECI1 antibodies in multiplex immunofluorescence studies?

When incorporating ECI1 antibodies into multiplex immunofluorescence studies:

• Antibody panel design:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies (like CAB1211) , implement sequential staining with stripping between rounds

• Spectral considerations:

  • Choose fluorophores with minimal spectral overlap

  • Implement proper controls for spectral unmixing

  • Consider ECI1's mitochondrial localization when selecting other markers

• Optimization steps:

  • Validate each antibody individually before combining

  • Determine optimal concentration for each antibody in the multiplex panel

  • Test for potential epitope blocking when multiple antibodies target nearby regions

• Analysis approach:

  • Implement quantitative colocalization analysis

  • Consider advanced image analysis methods like AQUA scoring

  • Use appropriate statistical methods for analyzing multiplex data

• Validation strategy:

  • Include single-stain controls alongside multiplex samples

  • Verify staining patterns match those observed in single-stain experiments

The integration of ECI1 detection with other metabolic markers provides valuable contextual information about its functional role in cellular metabolism.